Oric Pharmaceuticals, Inc. has reported a series of significant stock transactions involving its Chief Financial Officer, Dominic Piscitelli. The transactions, filed on October 21, 2026, highlight a proactive approach to managing equity stakes by the company's executive leadership. This development is noteworthy as it may impact investor sentiment and discussions around executive compensation in the pharmaceutical industry.
Background
Oric Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol ORIC. As a non-accelerated filer, Oric has been active in filing various reports, including recent submissions of Form 4 and Form 8-K.
What the Filing Says
The SEC filing indicates that on October 20, 2026, Piscitelli executed multiple transactions involving the company's common stock. Specifically, he acquired 14,000 shares through a stock option exercise at a price of $4.36 per share. Additionally, he sold 14,000 shares at a weighted average price of $13.5279, following a Rule 10b5-1 trading plan adopted earlier in the year.
Impact
This series of transactions may affect various stakeholders, including investors and analysts monitoring executive actions and compensation practices. The reported sales and acquisitions suggest a strategic management of personal holdings, which could influence perceptions of corporate governance and executive alignment with shareholder interests.
What's Next
The filing does not specify what happens next regarding further transactions or company announcements.